The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
Currently, molecular testing occurs at the tail end of the diagnostic workflow for inherited bleeding disorders.